AR052150A1 - 5-amino-4-hidroxi-2-isopropil-7-[4-metoxi-3-(3-metoxipropoxi) bencil] -8-metil-nonamidas - Google Patents

5-amino-4-hidroxi-2-isopropil-7-[4-metoxi-3-(3-metoxipropoxi) bencil] -8-metil-nonamidas

Info

Publication number
AR052150A1
AR052150A1 ARP050105156A ARP050105156A AR052150A1 AR 052150 A1 AR052150 A1 AR 052150A1 AR P050105156 A ARP050105156 A AR P050105156A AR P050105156 A ARP050105156 A AR P050105156A AR 052150 A1 AR052150 A1 AR 052150A1
Authority
AR
Argentina
Prior art keywords
amino
alkylamino
mono
optionally
nonamids
Prior art date
Application number
ARP050105156A
Other languages
English (en)
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of AR052150A1 publication Critical patent/AR052150A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Composiciones farmacéuticas que las contienen y uso como inhibidores de la renina. Reivindicacion 1: Compuesto de la formula (1), en la cual: R es heterociclilo que está unido a través de un átomo de carbono y está mono- o polisustituido con alquilo C1-6, trifluormetilo, nitro, amino, alquilamino C1-6, di-alquilaminoC1-6, alquenilo C2-6, alquinilo C2-6, alcoxilo C1-6, alquilcarboniloxilo C1-6, alquilcarbonilamino C0-6, alcoxicarbonilamino C1-6, hidroxilo, halogeno, oxido, ciano, carbamoilo opcionalmente N-mono- o N,N-di-alquiladoC1-8, carboxilo o alquilendioxilo C1-6 opcionalmente esterificados o está sustituido con oxo y mono- o polisustituido con alquilo C1-6, trifluormetilo, nitro, amino, alquilamino C1-6, di-alquilamino C1-6, alquenilo C2-6, alquinilo C2-6, alcoxilo C1-6, alquilcarboniloxilo C1-6, alquilcarbonilamino C0-6, alcoxicarbonilamino C1-6, hidroxilo,, halogeno, oxido, ciano, carbamoilo opcionalmente N-mono- o N,N-di-alquiladoC1-8, carboxilo o alquilendioxilo C1-6 opcionalmente esterificados, y su sal, especialmente sal util desde el punto de vista farmacéutico.
ARP050105156A 2004-12-10 2005-12-09 5-amino-4-hidroxi-2-isopropil-7-[4-metoxi-3-(3-metoxipropoxi) bencil] -8-metil-nonamidas AR052150A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH20492004 2004-12-10

Publications (1)

Publication Number Publication Date
AR052150A1 true AR052150A1 (es) 2007-03-07

Family

ID=35668936

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105156A AR052150A1 (es) 2004-12-10 2005-12-09 5-amino-4-hidroxi-2-isopropil-7-[4-metoxi-3-(3-metoxipropoxi) bencil] -8-metil-nonamidas

Country Status (10)

Country Link
US (1) US20080167381A1 (es)
EP (1) EP1819675A1 (es)
JP (1) JP2008523036A (es)
CN (1) CN101076518A (es)
AR (1) AR052150A1 (es)
BR (1) BRPI0518963A2 (es)
CA (1) CA2590252A1 (es)
IL (1) IL183771A0 (es)
TW (1) TW200633983A (es)
WO (1) WO2006061427A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095876A1 (en) 2004-04-01 2005-10-13 Cucumber Limited Delivery and storage of goods
US8058307B2 (en) * 2005-09-17 2011-11-15 Novartis Ag Alcanoic acid amides substituted by saturated O-heterocycles
EP1867329A3 (en) * 2006-06-14 2008-05-07 Speedel Experimenta AG 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamides as therapeutic compounds
EP1958666A1 (en) * 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
EP2075244A1 (en) 2007-12-24 2009-07-01 DSMIP Assets B.V. New route to building block for making renin inhibitors
WO2009080773A1 (en) * 2007-12-24 2009-07-02 Dsm Ip Assets B.V. Convergent synthesis of renin inhibitors and intermediates useful therein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE602005012481D1 (de) * 2004-03-19 2009-03-12 Speedel Experimenta Ag 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck

Also Published As

Publication number Publication date
CN101076518A (zh) 2007-11-21
WO2006061427A1 (en) 2006-06-15
JP2008523036A (ja) 2008-07-03
CA2590252A1 (en) 2006-06-15
US20080167381A1 (en) 2008-07-10
TW200633983A (en) 2006-10-01
IL183771A0 (en) 2007-09-20
EP1819675A1 (en) 2007-08-22
BRPI0518963A2 (pt) 2008-12-16

Similar Documents

Publication Publication Date Title
AR076171A1 (es) Pirazolopirimidinonas 1,6-disustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del alzheimer, epilepsia y otras enfermedades del sistema nervioso central.
AR052150A1 (es) 5-amino-4-hidroxi-2-isopropil-7-[4-metoxi-3-(3-metoxipropoxi) bencil] -8-metil-nonamidas
AR073689A1 (es) Derivados de azaindazol, antagonistas de receptores ccr1, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y de intermediarios, y uso para tratar enfermedades autoinmunes ,diabetes y alzheimer, entre otras.
CR9690A (es) 3-acilaminobenzanilidas insecticidas
ECSP088450A (es) Derivados de pirimidina 4-(3-aminopirazol) para uso como inhibidores de tirosina quinasa en el tratamiento de cáncer
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
BRPI0910368A2 (pt) "uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores"
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
BRPI0606318B8 (pt) composto, composição, e, uso de um composto
ES2422556T3 (es) Tratamiento de hepatitis vírica
AR062094A1 (es) Derivados de n'-ciano-n-halogenoalquil-imidamida
CO5640151A2 (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
AR069899A1 (es) Compuestos quimicos derivados de pirazol-triazina
CR8451A (es) Uso de derivados de n-arilhidracina para combatir pestes
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
PE20070438A1 (es) Derivados de 4-fenil-pirimidina-6-sustituida-2-carbonitrilo como inhibidores de catepsina k y catepsina s
CL2011001078A1 (es) Compuestos derivados de espirodihidrotetraazabenzoazuleno; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o tratamiento de dismenorrea, disfuncion sexual, hipertension, cirrosis hepatica y esquizofrenia entre otras.
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
AR058271A1 (es) Compuesto herbicida a base de fenoxaprop.
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
GT200400146A (es) Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal